Prescription and use of psychoactive medications among cancer patients and associated factors in lower and upper middle-income countries: systematic review.

Introduction

Cancer is a leading cause of both morbidity and mortality worldwide, imposing a growing health burden, especially for low- and middle-income countries (LMICs). These regions face a dual health challenge. As infectious diseases still contribute heavily to morbidity and mortality, the incidence of non-communicable diseases, including cancer, is highly increasing. According to the World Health Organization (WHO), over 70% of cancer-related deaths occur in LMICs, where access to specialized care and treatment remains limited. Projections suggest that by 2030, nearly three-quarters of all cancer deaths will occur in these regions [ 1 , 2 ].

Beyond the physical suffering caused by cancer, patients frequently experience psychological distress, including anxiety, depression, and other mental health disorders, which can further compromise their overall condition [ 3 , 4 ]. Even without a formal mental health diagnosis, nearly all cancer patients experience some degree of psychological distress at different stages of the disease, which can negatively impact their quality of life (QOL) and is associated with increased mortality [ 5 ]. A study conducted by Walker et al. found that the prevalence of depression and anxiety among cancer patients tends to be higher in low- and lower-middle-income countries compared to high-income countries [ 6 ]. Similarly, a study conducted in Africa revealed high rates of mental health disorders among cancer patients, with pooled prevalence estimates of 53.21% (95% CI: 47.47–58.94) for depression and 53.32% (95% CI: 46.85–59.80) for anxiety, highlighting a significant mental health burden in these populations. In this meta-analysis, self-administered questionnaires such as HADS, PHQ, and the Beck Depression Inventory were used to assess depression and anxiety, which may have contributed to higher prevalence estimates [ 7 ].

Moreover, a recent meta-analysis showed that depression after a cancer diagnosis is associated with a significantly increased risk of cancer-specific mortality across multiple cancer types [ 8 ].

Given the significant impact of mental health on cancer patients, it is essential to address their psychological needs, especially in low- and middle-income countries (LMICs), where recognition resources are limited, and mental health care is often overlooked. Despite the growing need for psychosocial support, the mental health burden among cancer patients in these regions has yet to be systematically assessed [ 6 ]. Furthermore, access to mental health services remains limited. Several barriers, such as the strong stigma surrounding mental health issues, a shortage of trained mental health professionals, the absence of mental health services within oncology care systems, and limited healthcare infrastructure, make it difficult for patients to access the psychological support they need [ 9 ]. The lack of integration and collaboration between mental health and cancer care services further exacerbates these challenges. As a result, many cancer patients in LMICs experience untreated psychological disorders, which can severely affect their overall well-being [ 10 , 11 ].

Appropriate care for psychological disorders in cancer patients includes psychotherapy as the first-line approach, with pharmacological treatment considered in cases of severe or psychotic symptoms, when psychotherapy is not effective, or when access to specialized psycho-oncology services is limited [ 12 ]. However, the prescription and use of psychoactive medications among cancer patients face significant challenges, particularly in LMICs. One important issue is the frequent late diagnosis of cancer, which complicates the overall management of both cancer and mental health [ 13 ]. Additionally, there is often a lack of monitoring regarding the medications that cancer patients are taking, which may lead to potential drug interactions, adverse effects, and potentially inappropriate use [ 14 ].

Despite the important role of psychoactive medications in managing mental health issues, there is a lack of comprehensive data on the prescribing and use of these medications among cancer patients in LMICs. This knowledge gap limits our ability to better understand disparities in access to psychological care and associated socio-economic factors. Understanding these patterns is important for identifying existing challenges and developing adapted strategies to improve mental care among cancer patients in resource-limited settings.

This study aimed to describe the prescription and use of psychoactive medications among cancer patients in LMICs and explore the factors influencing their prescription and use.

Methods

This systematic review was conducted following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines [ 15 ]. The study protocol was registered in the International Prospective Register of Systematic Reviews (PROSPERO) under the identification number CRD42024560300.

Search strategy

Searches were conducted across six databases including PubMed, Scopus, Google Scholar, SciELO, AJOL, and APA PsychArticles. The search terms focused on keywords related to prescription and medication use, and psychoactive medications in the context of cancer. The focus was also on studies from low- and middle-income countries (LMICs) according to the World Bank’s 2024 classification. In addition to the database searches, a manual search of relevant references was performed to ensure large coverage of the topic.

Study selection

The selection process adhered to predefined inclusion and non-inclusion criteria. Eligible studies were those conducted in low- and middle-income countries (LMICs), focusing on the use of psychoactive medications for the treatment of clearly defined psychological disorders in adult cancer patients. The medications considered belonged to the following Anatomical Therapeutic Chemical (ATC) Classifications: N05 “Psycholeptics” (N05A: Antipsychotics, N05B: Anxiolytics, N05C: Hypnotics and sedatives) and N06A (Antidepressants) according to the WHO Collaborating Centre for Drug Statistics Methodology.

Longitudinal and cross-sectional studies were included. Studies were excluded if they were systematic reviews, meta-analyses, abstracts, editorials, or case reports. Further exclusions applied to studies involving non-cancer patients, cancer patients not residing in LMICs, or those not receiving psychoactive medications.

Study quality assessment

The quality of the selected studies was independently assessed by two authors using the Newcastle–Ottawa Scale (NOS) for cohort studies, and its adapted version for cross-sectional studies [ 16 , 17 ]. These tools were specifically designed for each study type, focusing on three key domains: selection of study groups, comparability between groups, and assessment of outcomes. Cohort studies could receive a maximum of 9 points across these domains, while cross-sectional studies could receive a total of 10 points.

Any disagreements between the two assessors during the quality assessment process were resolved through discussion and consensus. If a consensus could not be reached, a third reviewer was consulted to make the final decision.

Data extraction

For each study, the following data were extracted: Study characteristics: including the publication year, authors’ names, country of the study, study design, sample size, and study objectives. Socio-demographic variables: including population characteristics such as age, gender, the study settings, which were classified as either population-based or hospital-based studies, income level, and health insurance (when reported). Clinical characteristics: cancer types and their prevalence (when reported), identified mental health disorders within the study population, classes and molecules of psychoactive medications, their prescription and use patterns, and medical data sources to assess the reliability of the information.

Results

Study selection

A total of 1237 articles were identified through the search strategy. After removing duplicates, 1160 articles were retained for further evaluation. Of these, 1066 were deemed irrelevant based on a review of their titles and abstracts. The remaining 94 articles were retrieved and assessed in full text, leading to the exclusion of 84 articles. In total, 10 articles met the inclusion criteria and were included in the review [ 13 , 18 – 26 ]. The flowchart for the selection and inclusion of studies is presented in (Fig .1 ). Fig. 1 Flowchart summarizing study identification and selection

Quality assessment

The quality of the included studies, consisting of two cohort studies and eight cross-sectional studies, was evaluated using the Newcastle–Ottawa Scale (NOS).

The cohort studies demonstrated a good methodological quality, receiving scores of 7 and 8 out of 9. Cross-sectional studies were rated between 6 and 8 out of 10. Most studies showed good performance in the selection and outcome domains reflecting appropriate sampling methods and reliable outcome measurements. However, comparability between study groups was the weakest area, as many studies lacked sufficient information on how potential confounding variables were controlled. Overall, some studies achieved good scores [ 7 , 8 ], while others were fairly scored 6 out of 10 (Supplementary Material 1 ).

Characteristics of included studies

The included studies comprised two cohort and eight cross-sectional studies conducted in middle-income countries, including China, India, Brazil, and Malaysia. Notably, no studies conducted in low-income countries were identified in the review. These studies mainly focused on patients with breast, lung, digestive, and prostate cancers, with the majority being hospital-based. The most commonly prescribed and used psychoactive medications were antidepressants, benzodiazepines, antipsychotics, and hypnotics, primarily used to treat depression, anxiety, and sleep disorders (Table 1 ). Table 1 General characteristics of included studies Variables Details Total number of studies (n) 10 Study design (n) Cohort (2), Cross-sectional (8) Countries China, India, Brazil, Malaysia Population-based study (n) 2 Hospital-based study (n) 8 Sample size (n) 48 111 (max)/56 (min) Gender distribution (%) Female: ~ 54%, Male: ~ 46% Most common cancer types Breast cancer, lung cancer, digestive cancers, prostate cancer Mental disorders observed Depression, anxiety, sleep disorders Prescribed and used psychoactive drugs Benzodiazepines, antidepressants antipsychotics, hypnotics min minimum, max maximum

Additional details regarding study objectives, medical data sources, cancer types, health insurance, and income levels were provided in (Supplementary Material 2 ).

The geographic distribution, income classification, and study design of the included studies were shown in (Fig. 2 ). Fig. 2 Geographic distribution, income classification and study design of included studies

Psychoactive medications prescribed and used among cancer patients

The studies included in this synthesis revealed that a variety of psychoactive drugs were commonly prescribed to cancer patients for managing mental health conditions, including anxiety, depression, sleep disturbances, and other psychotic disorders. The prescribed medications were antidepressants (Serotonin reuptake inhibitors (SSRIs), Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs), Tricyclic antidepressants (TCAs), and atypical antidepressants), benzodiazepines, non-benzodiazepine/Z-drugs, and antipsychotics (both typical/first-generation and atypical/second-generation). Benzodiazepines like lorazepam, alprazolam, and diazepam were prescribed for anxiety and sleep disturbances. Other related drugs, such as zolpidem and zopiclone, were also used for insomnia. In addition to benzodiazepines, antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs) such as sertraline and fluoxetine, were prescribed and used, alongside amitriptyline, mirtazapine, and other serotonin-norepinephrine reuptake inhibitors (SNRIs) like venlafaxine and duloxetine for depression. Antipsychotics, such as haloperidol (first-generation), and second-generation antipsychotics including quetiapine, olanzapine, risperidone, and aripiprazole, were used for managing psychotic symptoms and acute agitation. Across studies, psychotropic medication use showed marked variability. Some reported frequent use, especially among patients with comorbidities [ 18 ], or highlighted potentially inappropriate prescribing (potentially inappropriate medication (PIM) is defined as those in which the risk of adverse events from the drug outweighs the clinical benefits, and in particular, where there is a safer and more effective alternative) [ 27 ] of benzodiazepines and Z-drugs [ 19 , 23 ]. Others noted low or underuse of antidepressants [ 22 , 26 ], while in certain cases prescriptions were symptom-driven and not based on psychiatric diagnoses [ 13 ]. In addition, some studies reported that antidepressants were among the most frequent therapeutic classes of fall risk-increasing drugs (FRIDs) [ 20 ] or that about half of patients with depression received appropriate treatment [ 24 ]. More details about the studies’ selected populations, the psychoactive medications used and their respective classes, the proportion of patients with psychiatric diagnoses or psychiatric symptoms, and the methods used for their assessment are presented in Table 2 . Table 2 Summary of psychoactive medications prescribed and used among cancer patients with psychiatric disorders Study/country Population % of patients with psychiatric diagnosis/psychiatric symptoms Psychoactive medication classes (%) Medications % of patients with psychoactive medication Diagnostic or assessment method for psychiatric disorders Lam et al., 2024 China n = 1868 (Cancer patients who were newly prescribed psychotropic medications after cancer diagnosis) Only 18.6% ( n = 348/1868) had a documented diagnosis of psychiatric disorders: Depressive disorders ( n = 142/348, 40.8%) and Adjustment disorders ( n = 77/348, 22.1%) *Z-drugs (50.3%) *Serotonin reuptake inhibitors (SSRI), Tricyclic antidepressants (TCAs), and atypical antidepressants (32.8%) *Conventional antipsychotics and Atypical antipsychotics (31.0%) *Benzodiazepines (30.3%) *Zopiclone, Zolpidem. *Sertraline, Fluoxetine, Amitriptyline, Trazodone *Haloperidol, Quetiapine *Diazepam, Lorazepam The use of psychotropic medication is common (20%) among patients with cancer Psychotropic prescriptions were more likely prescribed in patients with multiple comorbidities NI Mohamed et al., 2024 India n = 125 (Cancer patients registered for palliative care at home) Anxiety (50%), depressive symptoms (22%) and psychosis (18%) *Benzodiazepines (56.8) *Tricyclic antidepressant, atypical antidepressant and Serotonin reuptake inhibitors (SSRI) (31.8%) *Atypical antipsychotics (43.1%) *Conventional antipsychotics. (13.6%) *Alprazolam, Lorazepam, Clonazepam *Amitriptyline, Mirtazapine and SSRIs *Quetiapine, Olanzapine, Risperidone *Haloperidol Psychotropic medication was used in 35.2% of patients, mostly initiated by palliative care (75%), with psychiatrists involved in only (25%). Prescriptions were largely symptom-driven, not based on psychiatric diagnosis Most prescriptions (63%) were symptom-driven. Only 36% of prescriptions targeted specific diagnoses Tian et al., 2022 China n = 6160 (Outpatients (age ≥ 65 years) with cancer and multimorbidity) NI *Benzodiazepines *Z-drugs *Estazolam, Alprazolam, Clonazepam, Diazepam. *Eszopiclone, Zolpidem One of the most common potentially inappropriate medication used were benzodiazepines and Z-drug hypnotics, accounting for 27.7% of all identified PIMs ( n = 2427) NI Machado et al., 2022 Brazil n = 153 (Patients with multiple myeloma and treated in the oncology and hematology departments of a capital city in south-east Brazil) Depression (4.6%) *Serotonin reuptake inhibitors (SSRIs), Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs), Tricyclic antidepressants (TCA), and Atypical antidepressants (20.5%) *Benzodiazepines (5.1%) *Benzodiazepines (5.1%) *Z-drugs (5.1%) * Conventional and Atypical antipsychotics (4.0%) *Fluoxetine, Escitalopram, Citalopram, Sertraline, Duloxetine, Venlafaxine, Amitriptyline, Imipramine, Nortriptyline, Mirtazapine, Trazodone, Vortioxetine *Clonazepam *Alprazolam, Lorazepam, Bromazepam *Zolpidem * Haloperidol, Chlorpromazine, and Quetiapine, Aripiprazole Antidepressants were among the most frequent therapeutic classes of fall risk-increasing drugs (FRIDs), accounting for 20.5% of cases NI Pu et al., 2022 China n = 152 (Patients with advanced cancer who received antidepressant intervention with Sertraline) Depression (41.5%) Anxiety (26.3%) Comorbid anxiety and depression (20.4%) *Serotonin reuptake inhibitors (SSRI) *Serotonin reuptake inhibitors (SSRI) and benzodiazepine *Sertraline *Sertraline and Diazepam 142 patients had completed sertraline intervention for ≥ 1 week Diazepam was added for 45 patients (31.7%) Hospital Anxiety and Depression Scale score (HADS) patients were categorized into 4 risk groups: high (HADS score, ≥ 15), medium (10–14 points), low (8–10 points), and no (≤ 7 points) risk Bai et al., 2020 China n = 48,111 (Cancer patients identified in the insurance database, who were prescribed at least one psychotropic medication) Mania, anxiety, insomnia and depression *Conventional antipsychotics and Atypical antipsychotics (1.4%) *Benzodiazepines and non-benzodiazepine anxiolytic (6.1%) *Benzodiazepines and Z-drugs (14.2%) * Tricyclic antidepressants (TCA), Serotonin reuptake inhibitors (SSRI) (0.9%) *Haloperidol, Droperidol and Chlorpromazine, Olanzapine, Risperidone *Diazepam, Alprazolam, Lorazepam, Oxazepam and Buspirone *Midazolam, Estazolam and Zolpidem, Zopiclone *Amitriptyline, Doxepin, Melitracen and Paroxetine, Escitalopram The prevalence of psychotropic medication use in Chinese adult cancer patients was 18.5% NI Reis et al., 2017 Brazil n = 160 (Patients aged 60 and over in an outpatient onco-hematology clinic at a university hospital in Brazil) Depression (10.2%) *Benzodiazepine (10.5%) *Tricyclic antidepressant (TCA) and Serotonin reuptake inhibitors (SSRI) (7.6%) *Diazepam, *Amitriptyline, Nortriptyline. and Paroxetine The prevalence of potential inappropriate use of medicines (PIM) among elderly outpatients in oncology is 48.1% The most commonly used PIMs include benzodiazepines (10.5%) and antidepressants (7.6%) NI Reinert et al., 2015 Brazil n = 56 (Cancer patients seen at the oncology clinic) Depression (26.7%) *Serotonin reuptake inhibitors (SSRI) *Tricyclic antidepressants (TCA) *Serotonin and Norepinephrine Reuptake Inhibitors (SNRI) *Fluoxetine, Escitalopram, Paroxetine, *Amitriptyline, Imipramine. *Venlafaxine Half of patients who screened positive for depression received antidepressant treatment 53.3% (8 of 15 depressed patients) Beck Depression Inventory-II (BDI-II), for assessment of depressive symptoms cutoff point of 20 points was chosen Zhao et al., 2014 China n = 460 (Patients hospitalized for cancer were recruited from the oncology department of a university hospital in Beijing, China) Depressive disorders (25.9%): *Major depressive disorder (MDD): 12.6 *Dysthemia: 9.1 *Minor depressive disorder: 1.7 *Mood disorder: 2.4 Antidepressants (25.9%) NI Only 3.4% of depressed patients were recognized by their oncologists, just 2.5% received treatment, and 0.8% were referred for psychiatric care The Mini International Neuropsychiatric Interview 5.0 by eight trained psychiatrists Ng et al., 2014 Malaysia n = 3345 (Oncology patients between 2008 and 2012) NI Anxiolytics and hypnotics (12.3%), Antidepressants (7.8%) Antipsychotics (5.6%) NI Use of Psychotropic Drugs (12.6%) NI NI not indicated Not all percentages of psychoactive medication classes used and percentages of patients with psychiatric diagnosis or psychiatric symptoms were reported in the selected studies Asterisks (*) were used to list medications (column 5) and their respective psychoactive classes (column 4)

Factors influencing the prescription and use of psychoactive medications among cancer

Several factors influenced the prescription and the use of psychoactive medications among cancer patients. Comorbidities were common in this population and were associated with the use of potentially inappropriate medications (PIMs). According to Tian et al., older cancer patients with comorbidities faced a higher risk of using PIMs, with a prevalence of 32.7%, and benzodiazepines were the most frequently prescribed PIMs [ 19 ]. Furthermore, cancer patients with comorbidities who took five or more medications daily (polypharmacy) were more likely to use potentially inappropriate psychoactive medications, as highlighted by Reis et al. [ 23 ].

Socioeconomic factors also contributed to disparities in psychoactive drug use among cancer patients. Geographic and health insurance variations play an important role. Bai et al. reported that cancer patients covered by Urban Employee Basic Medical Insurance (UEBMI) are more likely to use psychotropic medications compared to those insured under Urban Rural Resident Basic Medical Insurance (URRBMI) (OR = 1.18, 95% CI = 1.15–1.20). Additionally, there was a notable regional imbalance within the same country, with a significantly higher prevalence of psychoactive drug use observed among cancer patients in the Eastern region of China compared to the Western region (OR = 2.33, 95% CI = 2.27–2.40) [ 22 ].

These disparities are further compounded by the under-recognition and under-treatment of depression in cancer patients, as highlighted by several studies. For instance, Zhao et al. observed a high prevalence and a very low recognition rate of depression among Chinese cancer inpatients [ 25 ]. In Brazil, a study revealed that only half of the patients who screened positive for depression using the Beck Depression Inventory-II (BDI-II) received appropriate antidepressant treatment [ 24 ].

Ng et al. suggested that low prescription rates of psychoactive medications could be due to the underdiagnosis of depression or the increased caution in prescribing such drugs to cancer patients [ 26 ]. Lam et al. reinforced this notion, reporting that the low proportion of documented psychiatric diagnoses may reflect significant underdiagnosis of mental disorders in this population [ 18 ]. In India, only a quarter of psychoactive prescriptions were initiated by psychiatrists, with most prescriptions being driven by the need to manage specific symptoms rather than addressing underlying psychiatric conditions [ 13 ].

Discussion

The prescription and use of psychoactive medications among cancer patients highlight the heavy burden of mental health conditions such as anxiety, depression, sleep disturbances, and other psychotic disorders within this population [ 28 ]. These conditions severely impact the cancer patient’s quality of life, leading to a notable decline in overall well-being and negatively affecting treatment outcomes [ 29 ]. Our findings reveal a considerable variability in the prescription and use of these medications, influenced by a range of clinical, systemic, and sociocultural factors.

Across studies, the use of psychoactive medication varied widely, from frequent use among patients with comorbidities in some cases to underuse in others [ 18 , 26 ]. Prescriptions were sometimes symptom-driven rather than diagnosis-based [ 13 ]. Additional concerns emerged regarding potentially inappropriate prescribing in older adults [ 20 ]. Moreover, evidence from the Brazilian study revealed that only about half of patients with depression received adequate treatment [ 24 ].

In high-income countries, cancer survivors show a higher use of psychotropic medications compared to the general population. In the United States, 17–19% of cancer adults under 65 and 15–16% of those aged 65 and older report using such drugs, versus only 9–12% among adults without a cancer history. Antidepressants represent the most frequently prescribed class, followed by anti-anxiety medications [ 30 ]. Comparable trends have been observed in the Netherlands, where psychotropic prescriptions are frequent among cancer patients and tend to rise further in the terminal stage of illness [ 31 ].

In LMICs, despite the high prevalence of depression and anxiety, these disorders remain frequently underdiagnosed among cancer patients, particularly in those with advanced disease ​[ 32 ]. This underdiagnosis is particularly concerning, as psychological distress in cancer patients can exacerbate physical symptoms and affect overall quality of life. Several barriers contribute to this under recognition, including the lack of integration between oncology and mental health services, and limited access to mental health professionals, issues that are especially pronounced in low- and middle-income countries [ 11 ].

Additionally, cultural beliefs, such as the perception that cancer is a form of divine punishment, and stigma surrounding mental health can contribute to the underdiagnosis of mental health disorders [ 25 , 33 , 34 ]. In many African settings, mental illness is also interpreted as spiritual possession or personal weakness, making patients less likely to report symptoms or seek formal care. Instead, many turn to traditional healers or religious leaders before presenting to medical services [ 35 , 36 ].

Furthermore, older cancer patients with comorbid conditions are particularly vulnerable to potentially inappropriate medication (PIM) use. Managing multiple medications increases the risk of drug interactions, adverse effects, and inappropriate prescribing. Psychoactive drugs such as benzodiazepines and antidepressants, though commonly prescribed for anxiety or depression, can pose significant risks in the elderly, including cognitive decline and increased risk of falls [ 19 , 20 , 23 ].

Socioeconomic and structural factors also contribute to disparities in psychoactive medication use. Geographic location is a key determinant, with patients in urban areas more likely to have access to comprehensive care, specialized providers, and mental health services. In contrast, rural populations often face delayed diagnosis, limited treatment options, and restricted access to medications and psychosocial interventions [ 37 , 38 ].

Similarly, disparities in health insurance coverage influence access to treatment. Patients with more comprehensive insurance plans, such as those typically offered to urban employees, are more likely to benefit from a broader range of healthcare services, including access to medications for mental health conditions. Conversely, those covered by more basic insurance plans, such as the URRBMI, which is often the case for rural populations or low-income groups, may face higher out-of-pocket costs [ 22 , 39 , 40 ]. This is further aggravated by the limited availability of psychotropic medications in public health systems of LMICs, where essential psychiatric drugs are frequently out of stock or only available in urban hospitals. Affordability is also a barrier, especially when prescriptions require out-of-pocket payment in the absence of universal mental health coverage [ 41 ].

Healthcare system inequalities further aggravate the situation. In regions where mental health is not integrated into cancer care, or where there is a shortage of trained professionals, patients may not receive psychological assessments or treatment, including the prescription of appropriate psychoactive medications [ 42 , 43 ].

Both patients and healthcare providers may face perceptual barriers related to the use of psychoactive medications. Concerns about potential side effects, risks of dependency, and insufficient understanding of their therapeutic role can affect the acceptance, prescription, and adherence to these treatments in cancer care [ 44 ].

Moreover, there is a lack of reliable mental health data in many LMICs, limiting the ability to develop effective public health policies and allocate resources appropriately. Mental health is often deprioritized in national healthcare agendas, and systems for surveillance or psychiatric registries are rarely established [ 11 , 45 ]. In contrast to high-income countries, where large-scale and high-quality epidemiological studies provide valuable insights into prescription patterns, similar data are largely lacking in LMICs. This gap limits the ability to comprehensively assess psychoactive medication use and prescribing practices in LMICs. It is also important to note that some regions of the world are not represented, notably the Middle East, Europe, and Africa, which include several low- and middle-income countries (LMICs). Although the countries included in this review share to some extent similar structural challenges in psycho-oncology care (access to diagnostic facilities, access to and availability of medicines) [ 46 – 48 ], these findings are country-specific and should not be interpreted as capturing the full diversity of middle-income countries.

This study has several strengths and limitations. One strength is its comprehensive analysis of factors influencing psychoactive medications’ use and prescription in cancer patients in resource-limited countries, including clinical, social, and economic aspects, as well as geographic and insurance disparities. However, a limitation is that we were unable to find studies from low-income countries, where access to healthcare is more restricted. Additionally, as a systematic review, we relied on existing literature, which may not fully capture individual patient experiences, such as personal beliefs and attitudes toward mental health that could also impact medication use. Furthermore, the review lacked access to some data, such as patient-reported outcomes, which could have provided more insights about patient perspectives.

Conclusion

In conclusion, this review highlights the variability and complexity of psychoactive medications prescribing and use among cancer patients. Their use is shaped by multiple factors, including comorbidities, polypharmacy in older adults, and socioeconomic disparities that limit access to healthcare and medicines.

Future research could focus on longitudinal or qualitative studies exploring the personal, cultural, and contextual factors influencing mental health treatment in cancer patients, offering deeper insights into their experiences and needs. In addition, strengthening mental health awareness and prevention, alongside regular medication reviews especially for older adults could help reduce the use of potentially inappropriate medications and minimize harmful drug interactions. Addressing these gaps has the potential to improve both psychological well-being and clinical outcomes, contributing to more comprehensive and equitable cancer care.

Supplementary Information

Below is the link to the electronic supplementary material. Supplementary Material 1 (PDF 47.4 KB) Supplementary Material 2 (PDF 117 KB)

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Acknowledgements

None

Author contribution

Tassadit Merabtine: Writing – review & editing, Writing – original draft, Visualization, Project administration, Methodology, Investigation, Formal analysis, Data curation. **Dieu donné Gnonlonfoun:** Writing – review & editing, Validation, Supervision, Project administration, Methodology, Investigation, Conceptualization. **Elodie Marcellaud:** Writing – review & editing. **Sarah Altayyar:** Writing – review & editing. **Zeinab Tarhini:** Writing – review & editing. **Niki Christou:** Writing – review & editing, Validation, Supervision, Project administration, Methodology, Investigation, Conceptualization. **Jeremy Jost:** Writing – review & editing, Validation, Supervision, Project administration, Methodology, Investigation, Conceptualization.

Funding

Open access funding provided by Université de Limoges. The INSPIRE-UAC project, funded by the French Development Agency (AFD) – through the National Research Agency (ANR), under the Africa-France Academic Partnerships (PeA) program/project -ANR-23-PEA3-0005–01.

Data availability

No datasets were generated or analysed during the current study.

Declarations

Competing interests

The authors declare no competing interests.

References

1. Pramesh CS Badwe RA Bhoo-Pathy N Booth CM Chinnaswamy G Dare AJ Priorities for cancer research in low- and middle-income countries: a global perspective Nat Med 2022 28 4 649 657 10.1038/s41591-022-01738-x 35440716 PMC9108683 Pramesh CS, Badwe RA, Bhoo-Pathy N, Booth CM, Chinnaswamy G, Dare AJ et al (2022) Priorities for cancer research in low- and middle-income countries: a global perspective. Nat Med 28(4):649–657 35440716 10.1038/s41591-022-01738-x PMC9108683

2. Cancer |WHO | (2024) Regional Office for Africa. Available from: https://www.afro.who.int/health-topics/cancer . Accessed 4 Oct 2024

3. Ostovar S ModarresiChahardehi A MohdHashim IH Othman A Kruk J Griffiths MD Prevalence of psychological distress among cancer patients in Southeast Asian countries: a systematic review Eur J Cancer Care (Engl) 2022 31 6 e13669 35934684 10.1111/ecc.13669 PMC9786346 Ostovar S, ModarresiChahardehi A, MohdHashim IH, Othman A, Kruk J, Griffiths MD (2022) Prevalence of psychological distress among cancer patients in Southeast Asian countries: a systematic review. Eur J Cancer Care (Engl) 31(6):e13669 35934684 10.1111/ecc.13669 PMC9786346

4. Ebob-Anya BA Bassah N Psychosocial distress and the quality of life of cancer patients in two health facilities in Cameroon BMC Palliat Care 2022 21 1 96 10.1186/s12904-022-00981-w 35650571 PMC9158288 Ebob-Anya BA, Bassah N (2022) Psychosocial distress and the quality of life of cancer patients in two health facilities in Cameroon. BMC Palliat Care 21(1):96 35650571 10.1186/s12904-022-00981-w PMC9158288

5. Benton JZ Bergerot CD Woodruff P Williams SB Wallis CJD Klaassen Z Mental health screening and diagnosis in cancer patients: impact on mortality and suggestion of racial bias Cancer 2022 128 2 234 236 10.1002/cncr.33901 34550606 Benton JZ, Bergerot CD, Woodruff P, Williams SB, Wallis CJD, Klaassen Z (2022) Mental health screening and diagnosis in cancer patients: impact on mortality and suggestion of racial bias. Cancer 128(2):234–236 34550606 10.1002/cncr.33901

6. Walker ZJ Xue S Jones MP Ravindran AV Depression, anxiety, and other mental disorders in patients with cancer in low- and lower-middle–income countries: a systematic review and meta-analysis JCO Glob Oncol 2021 7 1233 1250 10.1200/GO.21.00056 34343029 PMC8457869 Walker ZJ, Xue S, Jones MP, Ravindran AV (2021) Depression, anxiety, and other mental disorders in patients with cancer in low- and lower-middle–income countries: a systematic review and meta-analysis. JCO Glob Oncol 7:1233–1250 34343029 10.1200/GO.21.00056 PMC8457869

7. Nakie G Melkam M Takelle GM Fentahun S Rtbey G Andualem F Depression, anxiety and associated factors among cancer patients in Africa; a systematic review and meta-analysis study BMC Psychiatry 2024 24 1 939 10.1186/s12888-024-06389-5 39716105 PMC11668085 Nakie G, Melkam M, Takelle GM, Fentahun S, Rtbey G, Andualem F et al (2024) Depression, anxiety and associated factors among cancer patients in Africa; a systematic review and meta-analysis study. BMC Psychiatry 24(1):939 39716105 10.1186/s12888-024-06389-5 PMC11668085

8. Ungvari Z, Fekete M, Buda A, Lehoczki A, Fekete JT, Varga P et al (2025) Depression increases cancer mortality by 23–83%: a meta-analysis of 65 studies across five major cancer types. GeroScience. Available from: 10.1007/s11357-025-01676-9. Accessed 22 Sep 2025

9. Depression symptoms (2024) How to manage depression. Available from: https://www.cancer.org/cancer/managing-cancer/side-effects/emotional-mood-changes/depression.html . Accessed 24 Oct 2024

10. Park SJ Wai A Pavithran K Kunheri B Valsraj K Cancer and severe mental illness in low- and middle-income countries: the challenges and outlook for the future Psychooncology 2021 30 12 2002 2011 10.1002/pon.5796 34449954 Park SJ, Wai A, Pavithran K, Kunheri B, Valsraj K (2021) Cancer and severe mental illness in low- and middle-income countries: the challenges and outlook for the future. Psychooncology 30(12):2002–2011 34449954 10.1002/pon.5796

11. Rathod S Pinninti N Irfan M Gorczynski P Rathod P Gega L Mental health service provision in low- and middle-income countries Health Serv Insights 2017 28 10 1178632917694350 10.1177/1178632917694350 Rathod S, Pinninti N, Irfan M, Gorczynski P, Rathod P, Gega L et al (2017) Mental health service provision in low- and middle-income countries. Health Serv Insights 28(10):1178632917694350

12. Venkataramu VN Ghotra HK Chaturvedi SK Management of psychiatric disorders in patients with cancer Indian J Psychiatry 2022 64 Suppl 2 S458 10.4103/indianjpsychiatry.indianjpsychiatry_15_22 35602367 PMC9122176 Venkataramu VN, Ghotra HK, Chaturvedi SK (2022) Management of psychiatric disorders in patients with cancer. Indian J Psychiatry 64(Suppl 2):S458 35602367 10.4103/indianjpsychiatry.indianjpsychiatry_15_22 PMC9122176

13 Mohamed F Uvais NA Moideen S Cp RR Saif M Psychotropic medication prescriptions for home-based palliative care oncology patients Prim Care Companion CNS Disord 2024 26 2 23m03668 38728674 10.4088/PCC.23m03668 Mohamed F, Uvais NA, Moideen S, Cp RR, Saif M (2024) Psychotropic medication prescriptions for home-based palliative care oncology patients. Prim Care Companion CNS Disord 26(2):23m03668 38728674 10.4088/PCC.23m03668

14. Riechelmann R Girardi D Drug interactions in cancer patients: a hidden risk? J Res Pharm Pract 2016 5 2 77 78 10.4103/2279-042X.179560 27162799 PMC4843587 Riechelmann R, Girardi D (2016) Drug interactions in cancer patients: a hidden risk? J Res Pharm Pract 5(2):77–78 27162799 10.4103/2279-042X.179560 PMC4843587

15. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-analyses: the PRISMA statement. BMJ 339 2535

16. Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, Tugwell P (2000). Ottawa Hospital Research Institute. Available from: https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp . Accessed 13 Nov 2024

17. Modesti PA Reboldi G Cappuccio FP Agyemang C Remuzzi G Rapi S Panethnic differences in blood pressure in Europe: a systematic review and meta-analysis PLoS ONE 2016 11 1 e0147601 10.1371/journal.pone.0147601 26808317 PMC4725677 Modesti PA, Reboldi G, Cappuccio FP, Agyemang C, Remuzzi G, Rapi S et al (2016) Panethnic differences in blood pressure in Europe: a systematic review and meta-analysis. PLoS ONE 11(1):e0147601 26808317 10.1371/journal.pone.0147601 PMC4725677

18. Lam CS Lee CP Chan JWY Cheung YT Patterns and factors associated with the prescription of psychotropic medications after diagnosis of cancer in Chinese patients: a population-based cohort study Pharmacoepidemiol Drug Saf 2024 33 2 e5754 10.1002/pds.5754 38362653 Lam CS, Lee CP, Chan JWY, Cheung YT (2024) Patterns and factors associated with the prescription of psychotropic medications after diagnosis of cancer in Chinese patients: a population-based cohort study. Pharmacoepidemiol Drug Saf 33(2):e5754 38362653 10.1002/pds.5754

19. Tian F Yang R Chen Z Duan X Yuan P The prevalence and factors associated with potentially inappropriate medication use in Chinese older outpatients with cancer with multimorbidity J Geriatr Oncol 2022 13 5 629 634 10.1016/j.jgo.2022.02.006 35183489 Tian F, Yang R, Chen Z, Duan X, Yuan P (2022) The prevalence and factors associated with potentially inappropriate medication use in Chinese older outpatients with cancer with multimorbidity. J Geriatr Oncol 13(5):629–634 35183489 10.1016/j.jgo.2022.02.006

20. Machado TRL, Menezes de Pádua CA, Drummond PL de M, Silveira LP, Malta JS, Santos RMMD et al (2022) Use of fall risk-increasing drugs in older adults with multiple myeloma: a cross-sectional study. J Geriatr Oncol 13(4):493–8

21. Pu B Wang N Wang C Sun B Clinical observation on the benefits of antidepressant intervention in advanced cancer patients Medicine (Baltimore) 2022 101 26 e29771 10.1097/MD.0000000000029771 35776994 PMC9239637 Pu B, Wang N, Wang C, Sun B (2022) Clinical observation on the benefits of antidepressant intervention in advanced cancer patients. Medicine (Baltimore) 101(26):e29771 35776994 10.1097/MD.0000000000029771 PMC9239637

22. Bai L Xu Z Huang C Sui Y Guan X Shi L Psychotropic medication utilisation in adult cancer patients in China: a cross-sectional study based on national health insurance database Lancet Reg Health - West Pac 2020 1 5 100060 Bai L, Xu Z, Huang C, Sui Y, Guan X, Shi L (2020) Psychotropic medication utilisation in adult cancer patients in China: a cross-sectional study based on national health insurance database. Lancet Reg Health - West Pac 1(5):100060

23. Reis CM Dos Santos AG de Jesus Souza P Reis AMM Factors associated with the use of potentially inappropriate medications by older adults with cancer J Geriatr Oncol 2017 8 4 303 307 10.1016/j.jgo.2017.05.003 28602709 Reis CM, Dos Santos AG, de Jesus Souza P, Reis AMM (2017) Factors associated with the use of potentially inappropriate medications by older adults with cancer. J Geriatr Oncol 8(4):303–307 28602709 10.1016/j.jgo.2017.05.003

24. Reinert CdeA Ribas MR Zimmermann PR Drug interactions between antineoplastic and antidepressant agents: analysis of patients seen at an oncology clinic at a general hospital Trends Psychiatry Psychother 2015 37 2 87 93 10.1590/2237-6089-2015-0003 26222300 Reinert CdeA, Ribas MR, Zimmermann PR (2015) Drug interactions between antineoplastic and antidepressant agents: analysis of patients seen at an oncology clinic at a general hospital. Trends Psychiatry Psychother 37(2):87–93 26222300 10.1590/2237-6089-2015-0003

25. Zhao L Li X Zhang Z Song C Guo C Zhang Y Prevalence, correlates and recognition of depression in Chinese inpatients with cancer Gen Hosp Psychiatry 2014 36 5 477 482 10.1016/j.genhosppsych.2014.05.005 24961793 Zhao L, Li X, Zhang Z, Song C, Guo C, Zhang Y et al (2014) Prevalence, correlates and recognition of depression in Chinese inpatients with cancer. Gen Hosp Psychiatry 36(5):477–482 24961793 10.1016/j.genhosppsych.2014.05.005

26. Ng CG Mohamed S Wern TY Haris A Zainal NZ Sulaiman AH Comparison of psychotropic prescriptions between oncology and cardiology inpatients: result from a pharmacy database in a teaching hospital in Malaysia Asian Pac J Cancer Prev APJCP 2014 15 10 4261 4264 10.7314/APJCP.2014.15.10.4261 24935381 Ng CG, Mohamed S, Wern TY, Haris A, Zainal NZ, Sulaiman AH (2014) Comparison of psychotropic prescriptions between oncology and cardiology inpatients: result from a pharmacy database in a teaching hospital in Malaysia. Asian Pac J Cancer Prev APJCP 15(10):4261–4264 24935381 10.7314/apjcp.2014.15.10.4261

27. Tamura BK Bell CL Inaba M Masaki KH Outcomes of polypharmacy in nursing home residents Clin Geriatr Med 2012 28 2 217 236 10.1016/j.cger.2012.01.005 22500540 Tamura BK, Bell CL, Inaba M, Masaki KH (2012) Outcomes of polypharmacy in nursing home residents. Clin Geriatr Med 28(2):217–236 22500540 10.1016/j.cger.2012.01.005

28. Więckiewicz G, Weber S, Florczyk I, Gorczyca P (2024) Socioeconomic burden of psychiatric cancer patients: a narrative review. Cancers 16(6), 1108. https://www.mdpi.com/2072-6694/16/6/1108 . Accessed 11 Dec 2024

29. Pinquart M Duberstein PR Depression and cancer mortality: a meta-analysis Psychol Med 2010 40 11 1797 10.1017/S0033291709992285 20085667 PMC2935927 Pinquart M, Duberstein PR (2010) Depression and cancer mortality: a meta-analysis. Psychol Med 40(11):1797 20085667 10.1017/S0033291709992285 PMC2935927

30. Punekar RS Short PF Moran JR Use of psychotropic medications by U.S. cancer survivors Psychooncology 2012 21 11 1237 1243 10.1002/pon.2039 21905155 PMC4079257 Punekar RS, Short PF, Moran JR (2012) Use of psychotropic medications by U.S. cancer survivors. Psychooncology 21(11):1237–1243 21905155 10.1002/pon.2039 PMC4079257

31. Ng CG Boks MP Smeets HM Zainal NZ de Wit NJ Prescription patterns for psychotropic drugs in cancer patients; a large population study in the Netherlands Psychooncology 2013 22 4 762 767 10.1002/pon.3056 22351591 Ng CG, Boks MP, Smeets HM, Zainal NZ, de Wit NJ (2013) Prescription patterns for psychotropic drugs in cancer patients; a large population study in the Netherlands. Psychooncology 22(4):762–767 22351591 10.1002/pon.3056

32. Pitman A Suleman S Hyde N Hodgkiss A Depression and anxiety in patients with cancer BMJ 2018 25 361 k1415 10.1136/bmj.k1415 Pitman A, Suleman S, Hyde N, Hodgkiss A (2018) Depression and anxiety in patients with cancer. BMJ 25(361):k1415

33. Yeo SS Meiser B Barlow-Stewart K Goldstein D Tucker K Eisenbruch M Understanding community beliefs of Chinese-Australians about cancer: initial insights using an ethnographic approach Psychooncology 2005 14 3 174 186 10.1002/pon.831 15386778 Yeo SS, Meiser B, Barlow-Stewart K, Goldstein D, Tucker K, Eisenbruch M (2005) Understanding community beliefs of Chinese-Australians about cancer: initial insights using an ethnographic approach. Psychooncology 14(3):174–186 15386778 10.1002/pon.831

34. Tang L de Groot J Bultz BD Psychosocial oncology in China Chin-Ger J Clin Oncol 2009 8 3 123 128 10.1007/s10330-009-0010-1 Tang L, de Groot J, Bultz BD (2009) Psychosocial oncology in China. Chin-Ger J Clin Oncol 8(3):123–128

35. Ae-Ngibise K Cooper S Adiibokah E Akpalu B Lund C Doku V “Whether you like it or not people with mental problems are going to go to them”: a qualitative exploration into the widespread use of traditional and faith healers in the provision of mental health care in Ghana Int Rev Psychiatry Abingdon Engl 2010 22 6 558 567 10.3109/09540261.2010.536149 Ae-Ngibise K, Cooper S, Adiibokah E, Akpalu B, Lund C, Doku V et al (2010) “Whether you like it or not people with mental problems are going to go to them”: a qualitative exploration into the widespread use of traditional and faith healers in the provision of mental health care in Ghana. Int Rev Psychiatry Abingdon Engl 22(6):558–567

36. Mendenhall E De Silva MJ Hanlon C Petersen I Shidhaye R Jordans M Acceptability and feasibility of using non-specialist health workers to deliver mental health care: stakeholder perceptions from the PRIME district sites in Ethiopia, India, Nepal, South Africa, and Uganda Soc Sci Med 2014 1982 118 33 42 10.1016/j.socscimed.2014.07.057 Mendenhall E, De Silva MJ, Hanlon C, Petersen I, Shidhaye R, Jordans M et al (2014) Acceptability and feasibility of using non-specialist health workers to deliver mental health care: stakeholder perceptions from the PRIME district sites in Ethiopia, India, Nepal, South Africa, and Uganda. Soc Sci Med 1982(118):33–42

37. Shawahna R, Debay M, Rahman N ur (2014) Inequalities in health care and behaviour in patients with diabetes and concurrent hypertension in Lahore, Pakistan. Tanzan J Health Res 15(4). Available from: http://www.ajol.info/index.php/thrb/article/view/89747 . Accessed 17 Apr 2024

38. Iamtrakul P Chayphong S Gao W Assessing spatial disparities and urban facility accessibility in promoting health and well-being Transp Res Interdiscip Perspect 2024 1 25 101126 Iamtrakul P, Chayphong S, Gao W (2024) Assessing spatial disparities and urban facility accessibility in promoting health and well-being. Transp Res Interdiscip Perspect 1(25):101126

39. Meng Q Fang H Liu X Yuan B Xu J Consolidating the social health insurance schemes in China: towards an equitable and efficient health system Lancet Lond Engl 2015 386 10002 1484 1492 10.1016/S0140-6736(15)00342-6 Meng Q, Fang H, Liu X, Yuan B, Xu J (2015) Consolidating the social health insurance schemes in China: towards an equitable and efficient health system. Lancet Lond Engl 386(10002):1484–1492

40. Ma X Oshio T The impact of social insurance on health among middle-aged and older adults in rural China: a longitudinal study using a three-wave nationwide survey BMC Public Health 2020 1 20 1842 10.1186/s12889-020-09945-2 Ma X, Oshio T (2020) The impact of social insurance on health among middle-aged and older adults in rural China: a longitudinal study using a three-wave nationwide survey. BMC Public Health 1(20):1842

41. World Health Organization, Fundação Calouste Gulbenkian (2017) Improving access to and appropriate use of medicines for mental disorders. Geneva: World Health Organization 95 p. Available from: https://iris.who.int/handle/10665/254794 . Accessed 11 Jul 2025

42. Lawrence D, Kisely S (2010) Inequalities in healthcare provision for people with severe mental illness. J Psychopharmacol Oxf Engl. 24(4_suppl), 61–8

43. Deshields T Asvat Y The case for accelerating integrated mental health care in the cancer setting JCO Oncol Pract 2023 19 5 231 233 10.1200/OP.22.00840 36800568 Deshields T, Asvat Y (2023) The case for accelerating integrated mental health care in the cancer setting. JCO Oncol Pract 19(5):231–233 36800568 10.1200/OP.22.00840

44. Mosher CE Winger JG Hanna N Jalal SI Fakiris AJ Einhorn LH Barriers to mental health service use and preferences for addressing emotional concerns among lung cancer patients Psychooncology 2014 23 7 812 819 10.1002/pon.3488 24493634 PMC4082441 Mosher CE, Winger JG, Hanna N, Jalal SI, Fakiris AJ, Einhorn LH et al (2014) Barriers to mental health service use and preferences for addressing emotional concerns among lung cancer patients. Psychooncology 23(7):812–819 24493634 10.1002/pon.3488 PMC4082441

45. Acuña-Rodríguez MP, Fiorillo-Moreno O, Montoya-Quintero KF, Tejan Mansaray F (2025) Mental Health Workforce Inequities Across Income Levels: Aligning Global Health Indicators, Policy Readiness, and Disease Burden. Psychol Res Behav Manag 1449–1454. https://www.who.int/publications/i/item/9789240036703 . Accessed 11 Jul 2025

46. Shi Y Zhang L Fu J Shao R Yan J An analysis of accessibility of representative psychotropic medicine from the World Health Organization model list of essential medicines in developing countries with different income levels Value Health 2023 26 4 528 535 10.1016/j.jval.2022.11.009 36442833 Shi Y, Zhang L, Fu J, Shao R, Yan J (2023) An analysis of accessibility of representative psychotropic medicine from the World Health Organization model list of essential medicines in developing countries with different income levels. Value Health 26(4):528–535 36442833 10.1016/j.jval.2022.11.009

47. Barbui C Access and use of psychotropic medicines in low-resource settings Epidemiol Psychiatr Sci 2015 24 3 206 209 10.1017/S2045796015000268 25787227 PMC6998629 Barbui C (2015) Access and use of psychotropic medicines in low-resource settings. Epidemiol Psychiatr Sci 24(3):206–209 25787227 10.1017/S2045796015000268 PMC6998629

48. Saraceno B van Ommeren M Batniji R Cohen A Gureje O Mahoney J Barriers to improvement of mental health services in low-income and middle-income countries The Lancet 2007 370 9593 1164 1174 10.1016/S0140-6736(07)61263-X Saraceno B, van Ommeren M, Batniji R, Cohen A, Gureje O, Mahoney J et al (2007) Barriers to improvement of mental health services in low-income and middle-income countries. The Lancet 370(9593):1164–1174